These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 24473674

  • 1. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [Abstract] [Full Text] [Related]

  • 2. Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study.
    Chen H, Qi X, Li Y, Wu Q, Shi Q, Wang L, Li J, Zhao L, Zhang L, Zhou X, Fei Y, Liu J, Su J, Wu D, Yang Y, Jiang H, Zeng X, Zhang F, Zhao Y.
    Mod Rheumatol; 2021 Mar; 31(2):394-398. PubMed ID: 32613869
    [Abstract] [Full Text] [Related]

  • 3. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

  • 6. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [Abstract] [Full Text] [Related]

  • 7. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA, van der Vegt B, Meiners PM, Vissink A, Spijkervet FK, Bootsma H, Kroese FG.
    Clin Exp Rheumatol; 2017 Apr; 35(2):317-320. PubMed ID: 27908305
    [Abstract] [Full Text] [Related]

  • 8. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E.
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [Abstract] [Full Text] [Related]

  • 10. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Morel J, Pedriger A, Puechal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Zarnitsky C, Labetoulle M, Ravaud P, Mariette X.
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X.
    Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
    [Abstract] [Full Text] [Related]

  • 12. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC, Dos Santos LC, Fidelix T, Lekwitch I, Soares SB, Gasparini AF, Augusto JV, Junior NC, Trevisani VFM.
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [Abstract] [Full Text] [Related]

  • 14. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ.
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [Abstract] [Full Text] [Related]

  • 15. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
    Cho HJ, Yoo JJ, Yun CY, Kang EH, Lee HJ, Hyon JY, Song YW, Lee YJ.
    Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
    [Abstract] [Full Text] [Related]

  • 16. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J.
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et Inflammations and the French Society of Rheumatology.
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R172. PubMed ID: 24286296
    [Abstract] [Full Text] [Related]

  • 19. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.
    Arthritis Res Ther; 2006 Oct 30; 8(4):R129. PubMed ID: 16859536
    [Abstract] [Full Text] [Related]

  • 20. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2005 Sep 30; 52(9):2740-50. PubMed ID: 16142737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.